Phathom Pharmaceuticals, Inc. — Form 8-K Summary
Business Context and Reporting Period
Phathom Pharmaceuticals filed this Form 8-K on December 31, 2020, reporting an agreement entered into on December 30, 2020. The agreement supports commercial supply and packaging for vonoprazan-based products intended for sale in the United States.
Material Definitive Agreement
Phathom entered into a Supply and Packaging Services Agreement with Sandoz GmbH. Sandoz will supply commercial quantities of amoxicillin capsules and clarithromycin tablets, package them with Phathom’s vonoprazan product candidate into finished convenience packs, and sell the finished product to Phathom.
- Phathom must purchase specified quantities at an agreed price per pack.
- The price per pack is fixed for the first two years after U.S. launch and may subsequently be adjusted for Sandoz cost increases, subject to an annual cap.
- Phathom is subject to annual minimum purchase requirements after launch and must pay for any shortfall.
- Sandoz is not required to supply quantities above a maximum based on a percentage of Phathom’s forecasts.
- Phathom agreed to purchase exclusively from Sandoz the finished product, amoxicillin, and clarithromycin intended for U.S. sale for five years after launch.
Term, Termination, and Other Provisions
The initial term is five years from launch. Either party may terminate at the end of the initial term by providing notice before the end of the third year after launch. Without such notice, the agreement automatically extends for an additional three years, followed by further extensions only by mutual agreement.
Either party may terminate for an uncured material breach. The agreement also contains customary provisions covering forecasts, delivery, payments, transportation, intellectual property, confidentiality, warranties, and indemnification.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial results. It also does not disclose the per-pack price, minimum or maximum pack quantities, launch date, potential shortfall payments, or the annual price-adjustment cap.
Outlook, Risks, and Unusual Items
- The agreement establishes a supply arrangement but does not guarantee regulatory approval or commercial launch of vonoprazan or the finished product.
- Minimum purchase obligations could result in payments to Sandoz if sales or demand are below required levels.
- Exclusive sourcing and Sandoz’s maximum supply obligation may limit Phathom’s flexibility and create supply or capacity risk.
- Pricing may increase after the first two years following launch, subject to the undisclosed annual cap.
- Phathom intends to redact certain portions of the agreement for confidentiality.
Key Facts for Investors to Verify
- Regulatory status and expected U.S. launch timing for the vonoprazan-based product.
- Per-pack pricing, annual minimum purchase commitments, supply caps, and price-adjustment terms in the agreement exhibit.
- Potential financial exposure from minimum-volume shortfalls.
- Whether the agreement was subsequently amended, terminated, or supplemented.
- Disclosure of the agreement in Phathom’s Form 10-K for the year ended December 31, 2020.